March 7, 2002
Deborah J. Neff
Becton, Dickinson and Company
Edward J. Ludwig
President and CEO
Clinical Goals Drive Tool Development
What is the history of your organization’s involvement in life sciences?
Ludwig & Neff: BD Biosciences has been developing solutions for the life sciences since the 1970s, when BD pioneered the commercialization of flow cytometry.
What is your vision for the development of the life sciences market?
Ludwig & Neff: Our corporate purpose is to help all people live healthy lives, and BD Biosciences is a wonderful vehicle to do this and build a successful business at the same time. We do so by striving to become the recognized, leading provider of innovative tools, systems, and solutions to support the life sciences. With our tools, clinicians and researchers can better understand disease processes, improve diagnosis and disease management, and facilitate the discovery and development of new drugs. All of this will help improve human health.
We expect that BD Biosciences will become a more substantial part of BD’s overall business in the years to come.
What organizational assets have you developed to serve this community?
Ludwig & Neff: Success in BD Biosciences depends on human capital, so a key priority has been building the scientific and management capability to be a world leader. Those organizational assets include more than 200 Ph.D.s and 350 people in R&D, with recognized expertise in immunology, molecular biology, cell biology, and cell analysis. We speak the same language as researchers and clinicians doing important biomedical research and are active collaborators with government, academic, and industry partners.
Our human capital has enabled us to develop sustainable technology platforms that can be levered into a number of growth areas such as genomics, proteomics, drug discovery, and vaccine monitoring. We have also built a superior service capability both for application support in the field and for technical support and training.
What products and services does your company provide to the life sciences market?
Ludwig & Neff: Our key product lines include flow cytometry systems for cell analysis, antibody reagents for biomedical research, molecular biology reagents for studying genes and their function, cell growth and screening platforms for drug discovery, and labware consumables for basic and clinical research. We also provide services to support the development of new biomedical assays and applications, plus field service and engineering.
What new products and services do you have in development?
Ludwig & Neff: Here are a few:
• Multiplexed assay and array technology for a variety of platforms for analyzing multiple variables and for comparing multiple samples;
• Advanced immune function assays for enumerating cells to help determine the impact of diseases like AIDS on the immune system, to evaluate treatment options and their effectiveness, to monitor transplant patients, and to measure the immune response to novel vaccines; and
• Next-generation flow cytometry to enable researchers to be more effective in analyzing cells, their structure, and their function.
Return to main index page.